Heart failure and diabetes

Area of Science:

• Cardiology
• Endocrinology
• Metabolic Diseases

Background:

• Diabetes mellitus is a major risk factor for heart failure (HF) development.
• Diabetic patients are at increased risk for HF, classified as Stage A by the American Societies of Cardiology.
• Key contributors to HF in diabetes include coronary artery disease, hypertension, and diabetic cardiomyopathy.

Purpose of the Study:

• To outline the etiological factors, diagnostic approaches, and therapeutic strategies for heart failure in diabetic patients.
• To emphasize the importance of managing cardiovascular risk factors in diabetes to prevent HF.
• To clarify medication choices for diabetic patients with or at risk of HF.

Main Methods:

• Review of etiological factors: coronary artery disease, systemic hypertension, diabetic cardiomyopathy, renal insufficiency, and obesity.
• Diagnostic assessment mirroring non-diabetic subjects: clinical evaluation, echocardiography, and B-type natriuretic peptide levels.
• Therapeutic strategies including non-pharmacological measures, standard HF pharmacotherapy (e.g., beta-blockers), and careful selection of antihyperglycemic agents.

Main Results:

• Diabetes is a significant risk factor for heart failure.
• Diagnosis and treatment of HF in diabetes follow established guidelines, with specific considerations for antihyperglycemic agents.
• Effective management includes blood pressure and lipid control, ACE inhibitors for at-risk individuals, and improved glycemic control.

Conclusions:

• Diabetic patients require vigilant monitoring for heart failure.
• Standard heart failure medications, including beta-blockers, are safe and beneficial.
• Avoiding specific antihyperglycemic agents (biguanides, thiazolidinediones) is crucial in heart failure management, with exceptions for pioglitazone in early stages (NYHA I-II).